This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farrell, D. J.
Right arrow Articles by Felmingham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farrell, D. J.
Right arrow Articles by Felmingham, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1882-1884, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1882-1884.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Activities of Telithromycin against 13,874 Streptococcus pneumoniae Isolates Collected between 1999 and 2003

David J. Farrell* and David Felmingham

GR Micro Limited, London, United Kingdom

Received 15 October 2003/ Returned for modification 6 December 2003/ Accepted 20 January 2004

Telithromycin MICs for 13,874 Streptococcus pneumoniae isolates collected in the first 3 years of the global PROTEKT study (1999 to 2003) were studied. There was no change in the distribution of telithromycin MICs over this period, even in countries where telithromycin is in use. The telithromycin MICs for 10 isolates (0.07%) were >=4 µg/ml, and these 10 isolates contained erm(B); there was no evidence of reproducible clonal spread between centers.

* Corresponding author. Mailing address: Medical and Molecular Microbiology, GR Micro Limited, 7-9 William Rd., London NW1 3ER, United Kingdom. Phone: 44 (0)20 73887320. Fax: 44 (0) 20 73887324. E-mail: D.Farrell{at}grmicro.co.uk.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1882-1884, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1882-1884.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Isozumi, R., Ito, Y., Ishida, T., Osawa, M., Hirai, T., Ito, I., Maniwa, K., Hayashi, M., Kagioka, H., Hirabayashi, M., Onari, K., Tomioka, H., Tomii, K., Gohma, I., Imai, S., Takakura, S., Iinuma, Y., Ichiyama, S., Mishima, M., and the Kansai Community Acquired Pneumococcal Pne, (2007). Genotypes and Related Factors Reflecting Macrolide Resistance in Pneumococcal Pneumonia Infections in Japan. J. Clin. Microbiol. 45: 1440-1446 [Abstract] [Full Text]  
  • Al-Lahham, A., Appelbaum, P. C., van der Linden, M., Reinert, R. R. (2006). Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe. Antimicrob. Agents Chemother. 50: 3897-3900 [Abstract] [Full Text]  
  • Rantala, M., Haanpera-Heikkinen, M., Lindgren, M., Seppala, H., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan, (2006). Streptococcus pneumoniae Isolates Resistant to Telithromycin.. Antimicrob. Agents Chemother. 50: 1855-1858 [Abstract] [Full Text]  
  • Faccone, D., Andres, P., Galas, M., Tokumoto, M., Rosato, A., Corso, A. (2005). Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones. J. Clin. Microbiol. 43: 5800-5803 [Abstract] [Full Text]  
  • Rantala, M., Huikko, S., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan, (2005). Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002. Antimicrob. Agents Chemother. 49: 4180-4184 [Abstract] [Full Text]  
  • Farrell, D. J., Felmingham, D. (2005). The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 56: 795-797 [Full Text]  
  • Hisanaga, T., Hoban, D. J., Zhanel, G. G. (2005). Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 56: 447-450 [Abstract] [Full Text]  
  • Reinert, R. R., van der Linden, M., Al-Lahham, A. (2005). Molecular Characterization of the First Telithromycin-Resistant Streptococcus pneumoniae Isolate in Germany. Antimicrob. Agents Chemother. 49: 3520-3522 [Abstract] [Full Text]  
  • Zhanel, G. G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A., Hoban, D. J. (2005). Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary. Antimicrob. Agents Chemother. 49: 1943-1948 [Abstract] [Full Text]  
  • Zhanel, G. G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A., Hoban, D. J. (2004). Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 54: 1072-1077 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»